文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

部分有效登革热疫苗的伦理问题:菲律宾的经验教训

Ethics of a partially effective dengue vaccine: Lessons from the Philippines.
PubMed 文献 · Vaccine · 2020-07-10

Dengvaxia四价登革热疫苗在登革热流行国广泛许可,但大型队列研究发现其仅部分保护既往登革病毒感染者,却使血清阴性儿童致突破性登革热病情加重。研究利用修订的疫苗效力和安全性数据估算菲律宾逾80万名9岁接种儿童中住院和重症登革热病例,尽管4年疫苗效力为69%,预计仍将有逾千名接种的血清阴性和阳性儿童因重症登革热住院。作者提出加强监测改善照护,并建议通过增强IV期监测明确效力和安全性、获取可及敏感特异的血清学检测、阐明黄病毒免疫者中的安全性,且在缺乏可接受血清筛查时仅对签署知情同意者接种。

要点

  • Dengvaxia对既往登革感染者部分保护,但使血清阴性儿童致突破性登革热病情加重。
  • 菲律宾逾80万名9岁接种儿童中,预计逾千人因重症登革热住院。
  • 缺乏可接受血清筛查时,建议仅对签署知情同意者接种Dengvaxia。

核心结论

  • Dengvaxia存在部分保护与血清阴性儿童病情加重并存的伦理问题,需加强监测并审慎制定疫苗政策。

研究设计与样本

  • 基于修订的Dengvaxia效力和安全性数据,估算菲律宾逾80万名9岁接种儿童的住院和重症登革热病例。

主要发现

  • 4年疫苗效力为69%,但预计逾千名接种的血清阴性和阳性儿童因重症登革热住院。

关键数值与推荐

  • 疫苗效力69%(4年接种后),对象为菲律宾9岁接种儿童。
  • 推荐通过增强IV期监测明确疫苗效力和安全性。
  • 推荐获取可及、敏感、特异的血清学检测以识别既往野生型登革病毒感染。
  • 推荐阐明Dengvaxia在黄病毒免疫者中的安全性和效力。
  • 缺乏可接受血清筛查时,Dengvaxia仅对签署知情同意者接种。

临床怎么用

  • 接种前应筛查既往登革感染,缺乏可接受血清检测时仅对知情同意者接种。
  • 加强接种后监测以识别突破性登革热感染并改善照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to breakthrough DENV disease of enhanced severity. In 2019, the European Medicines Agency and the US FDA issued licenses that reconciled safety issues by restricting vaccine to individuals with prior dengue infections. Using revised Dengvaxia efficacy and safety data we sought to estimate hospitalized and severe dengue cases among the more than 800,000 9 year-old children vaccinated in the Philippines. Despite an overall vaccine efficacy of 69% during 4 years post-vaccination we project there will be more than one thousand vaccinated seronegative and seropositive children hospitalized for severe dengue. Assisting these children through a program of enhanced surveillance leading to improved care deserves widespread support. Clinical responses observed during breakthrough dengue infections in vaccinated individuals counsel prudence in design of vaccine policies. Recommendations concerning continued use of this dengue vaccine are: (1) obtain a better definition of vaccine efficacy and safety through enhanced phase 4 surveillance, (2) obtain a valid, accessible, sensitive, specific and affordable serological test that identifies past wild-type dengue virus infection and (3) clarify safety and efficacy of Dengvaxia in flavivirus immunes. In the absence of an acceptable serological screening test these unresolved ethical issues suggest Dengvaxia be given only to those signing informed consent.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Halstead SB, Katzelnick LC, Russell PK, et al. Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine. 2020. PMID: 32654899. doi:10.1016/j.vaccine.2020.06.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。